Today, Takeda announced the discontinuation of Natpara at the end of 2024. The notice can be found here. The notice mentioned several reasons: But there is good news: Takeda is producing
Forteo: some details. **Note that Forteo is not FDA approved for hypoparathyroidism** The Forteo pen is set to give a fixed dose of 20 microgram, which comes in a volume of
Here is the Joint American Society for Bone and Mineral Research (ASBMR) – Endocrine Society Guidance on Transitioning Hypoparathyroidism Patients from NATPARA®.
Takeda’s letter to Healthcare Providers: see below. My summary: A Prior Approval Supplement (PAS) that proposes a new septum and new needle to address the rubber particle issue has been submitted to the
Here is a letter I sent to insurance companies (your doctor should edit it to reflect your situation):
Forteo A few words about Forteo (recombinant human PTH[1-34], also called teriparatide).
The recall of Natpara in the US has caused significant concerns and uncertainties for patients with hypoparathyroidism who are currently on Natpara (PTH1-84) and their providers. The recall notice can
